AstraZeneca Inks $815M Deal To Develop Anemia Drug
British drug giant AstraZeneca LP has agreed to pay up to $815 million for the rights to an anemia treatment by San Francisco-based FibroGen Inc., which will be commercialized in markets...To view the full article, register now.
Already a subscriber? Click here to view full article